Search Results 341-350 of 17603 for Cytokines

1. A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2) - Mayo Clinic

   adequately respond to a cytokine release syndrome (CRS) event - Symptomatic active pulmonary disease or requiring supplemental oxygen - Known active ...

2. A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors - Mayo Clinic

   Dostarlimab enhanced effector T-cell functions, including cytokine production, in vitro. Since dostarlimab does not bind mouse PD-1, its single-agent ...

3. In Clinical Trials - Mayo Clinic Research

   ... cytokines. The aims of this project will focus on 1) testing protocols for efficient isolation of plasma-derived sEV from small volumes of sample, 2 ...

4. ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19 - Mayo Clinic

   Received monoclonal antibodies targeting cytokines (e.g., tumor necrosis factor (TNF) inhibitors, anti-IL-1 [e.g., anakinra, canakinumab], anti-IL-6 [e.g. ...

5. Kidney cancer - Symptoms and causes - Mayo Clinic

   Complete surgical metastasectomy of renal cell carcinoma in the post-cytokine era. The Journal of Urology. 2020; doi:10.1097/JU.0000000000000488. Dong H, et ...

6. Study of Oral LOXO-338 in Patients With Advanced Blood Cancers - Mayo Clinic

   therapy - Need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity Grade > 1 from CAR-T therapy - Ongoing ...

7. A Study to Evaluate Chemoradiotherapy with or without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer - Mayo Clinic

   RANKL infusion: Concurrent denosumab (which binds the cytokine RANKL) for any known indication is prohibited due to interaction with study medication.

8. Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy - Mayo Clinic

   Exposure to monoclonal antibodies, cytokines, growth factors, soluble receptors, other recombinant products, or fusion proteins within 6 months prior to the ...

9. A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies - Mayo Clinic

   Treatment with biological agents (including monoclonal antibodies and cytokines) within 28 days of the planned first dose of investigational product with the ...

10. Publications - Fahad Shuja, M.B.B.S. - Mayo Clinic

    Cytokine.2010;49()303-11. Butt MU, Sailhamer EA, Shuja F, Liu Y. Pharmacologic Resuscitation: Cell Protective Mechanisms of Histone Deacetylase Inhibition ...